Drug intelligence / Profile preview

N-oxo-2-(phenylsulfonylamino)ethanamide

Development stage: Unknown
Modality: Small Molecules

Overview

N-oxo-2-(phenylsulfonylamino)ethanamide is an experimental small molecule that belongs to the class of benzenesulfonamides, characterized by a sulfonamide group attached to a benzene ring. It acts as an inhibitor of macrophage metalloelastase (also known as matrix metalloproteinase 12, MMP12), which is involved in the degradation of extracellular matrix components and has been implicated in inflammatory processes and tissue remodeling. The compound has not been approved for any indication and remains at the experimental stage with no reported clinical trials or approved uses[1][4][5].

Other names: N-(2-nitroso-2-oxoethyl)benzenesulfonamide

Targets

MMP12 (Macrophage Metalloelastase)

Beyond the preview

Go deeper on N-oxo-2-(phenylsulfonylamino)ethanamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-oxo-2-(phenylsulfonylamino)ethanamide.

Explore the full profile